Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens
- 10 September 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Immunologic Research
- Vol. 46 (1-3), 23-31
- https://doi.org/10.1007/s12026-009-8120-y
Abstract
The GD2 ganglioside, displayed by five carbohydrate Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ residues attached to a ceramide chain that anchors the ganglioside in the cell membrane, is expressed on neuroectodermally derived tumors. GD2 has been used as a target for passive and active immunotherapy in patients with malignant melanoma and neuroblastoma. We have generated 47-LDA mimotope of GD2 by screening a phage display peptide library with anti-GD2 mAb 14G2a and reported that vaccination with the 47-LDA mimotope elicited GD2 cross-reactive IgG antibody responses as well as MHC class I-restricted CD8+ T cells to syngeneic neuroblastoma tumor cells. The cytotoxic activity of the vaccine-induced CTLs was independent of GD2 expression, suggesting recognition of a novel tumor-associated antigen cross-reacting with 47-LDA. Immunoblotting studies using 14G2a mAb demonstrated that this antibody cross-reacts with a 105 kDa glycoprotein expressed by GD2+ and GD2− neuroblastoma and melanoma cells. Functional studies of tumor cells grown in three-dimensional (3D) collagen cultures with 14G2a mAb showed decreases in matrix metalloproteinase-2 activation, a process regulated by 105 kDa activated leukocyte cell adhesion molecules (ALCAM/CD166). The CD166 glycoprotein was shown to be recognized by 14G2a antibody, and inhibition of CD166 expression by RNA interference ablated the cell sensitivity to lysis by 47-LDA-induced CD8+ T cells in vitro and in vivo. These results suggest that the vaccine-induced CTLs recognize a 47-LDA cross-reactive epitope expressed by CD166 and reveal a novel mechanism of induction of potent tumor-specific cellular responses by mimotopes of tumor-associated carbohydrate antigens.Keywords
This publication has 15 references indexed in Scilit:
- Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor CellsPublished by The American Association of Immunologists ,2008
- Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene deliveryCancer Immunology, Immunotherapy, 2007
- Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166/MEMD), a Novel Actor in Invasive Growth, Controls Matrix Metalloproteinase ActivityCancer Research, 2005
- Mechanisms for the Apoptosis of Small Cell Lung Cancer Cells Induced by Anti-GD2 Monoclonal AntibodiesPublished by Elsevier BV ,2005
- Dendritic cell maturation by innate lymphocytesThe Journal of Experimental Medicine, 2005
- Recruiting dendritic cells to improve antibody therapy of cancerProceedings of the National Academy of Sciences of the United States of America, 2005
- Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cellsProceedings of the National Academy of Sciences of the United States of America, 2005
- Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migrationEuropean Journal of Cell Biology, 2002
- Aberrant Glycosylation In Tumors And Tumor-Associated Carbohydrate AntigensAdvances in Cancer Research, 1989
- Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.Proceedings of the National Academy of Sciences of the United States of America, 1984